TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PYLERA

BISMUTH SUBCITRATE POTASSIUM
Infectious Disease Approved 2006-09-28
1
Indication
--
Phase 3 Trials
19
Years on Market

Details

Status
Prescription
First Approved
2006-09-28
Routes
ORAL
Dosage Forms
CAPSULE

PYLERA Approval History

Loading approval history...

What PYLERA Treats

2 indications

PYLERA is approved for 2 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Helicobacter pylori Infection
  • Duodenal Ulcer
Source: FDA Label

PYLERA Boxed Warning

POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans ( 5.1 )....

Drugs Similar to PYLERA

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACIPHEX
RABEPRAZOLE SODIUM
2 shared
EISAI MEDCL RES
Shared indications:
Duodenal UlcerHelicobacter pylori Infection
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE
BISMUTH SUBCITRATE POTASSIUM
2 shared
PH HEALTH
Shared indications:
Helicobacter pylori InfectionDuodenal Ulcer
CLARITHROMYCIN
CLARITHROMYCIN
2 shared
Teva
Shared indications:
Helicobacter pylori InfectionDuodenal Ulcer
ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM
2 shared
ZYDUS PHARMS
Shared indications:
Helicobacter Pylori InfectionDuodenal Ulcer
PRILOSEC
OMEPRAZOLE MAGNESIUM
2 shared
COVIS
Shared indications:
Duodenal UlcerHelicobacter pylori Infection
ARTHROTEC
DICLOFENAC SODIUM
1 shared
Pfizer
Shared indications:
Duodenal Ulcer
CARAFATE
SUCRALFATE
1 shared
AbbVie
Shared indications:
Duodenal Ulcer
DICLOFENAC SODIUM AND MISOPROSTOL
DICLOFENAC SODIUM
1 shared
MICRO LABS
Shared indications:
Duodenal Ulcer
ESOMEPRAZOLE SODIUM
ESOMEPRAZOLE SODIUM
1 shared
GLAND
Shared indications:
Duodenal Ulcer
FAMOTIDINE PRESERVATIVE FREE
FAMOTIDINE
1 shared
Hikma
Shared indications:
Duodenal Ulcer
LANSOPRAZOLE
LANSOPRAZOLE
1 shared
ZYDUS PHARMS
Shared indications:
Duodenal Ulcer
NEXIUM
ESOMEPRAZOLE MAGNESIUM
1 shared
AstraZeneca
Shared indications:
Duodenal Ulcer
PREVACID
LANSOPRAZOLE
1 shared
Takeda
Shared indications:
Duodenal Ulcer
RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE
1 shared
Dr. Reddy's
Shared indications:
Duodenal Ulcer
TALICIA
AMOXICILLIN
1 shared
TALICIA HOLDINGS
Shared indications:
Helicobacter pylori Infection
VOQUEZNA
VONOPRAZAN FUMARATE
1 shared
PHATHOM PHARMACEUTICALS INC
Shared indications:
Helicobacter Pylori Infection
VOQUEZNA DUAL PAK
AMOXICILLIN
1 shared
PHATHOM
Shared indications:
Helicobacter pylori Infection
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PYLERA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be c...

⚠️ BOXED WARNING

WARNING: POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.